THE TECHNOPOLICY NETWORK

The Global Community of Knowledge Regions



The Importance of SMEs in the **BioHealth Sector**

Riyadh, Saudi Arabia November 6th, 2013

> **Richard Bendis** President & CEO








The World According to Friedman

Hot, Flat, and Crowded









Global Innovation Imperative

- Innovation is Key to Growing and Maintaining a Country's competitive Position in the Global Economy and to address Global Challenges
- Collaboration among Small and Large Businesses, Universities, and Research Institutes is Essential for Innovation & Commercialization
- New Institutions and New Incentives, are increasingly important to support collaboration and foster innovation
- Competitive advantages are increasingly tied to human capital and innovation
- Economic growth is closely related to education/ workforce, energy, climate change, environmental, natural resource, geopolitical issues & entrepreneurship



OPEN INNOVATION MATTERS



The Six Driving Forces of Change

- Commoditization
- The Digital Revolution
- Social Media-ization throughout society
- Global Open Innovation
- The Turbulent World
- Acceleration (or running faster to stay in the same place)





Why is Innovation Essential?



"INNOVATION DISTINGUISHES BETWEEN A LEADER AND A FOLLOWER."

- STEVE JOBS

INNOVATION is the creation and transformation of knowledge into new products, processes, and services that meet market need....and interactions, entertainment forms, and ways of communicating and collaborating



"Never before in history has innovation offered promise of so much to so many in so short a time."


Bill Gates - Microsoft






Economic Development

- Economic Development is like a
- 4 legged stool:
 - Attraction
 - Retention
 - REINVENTION
 - Grow Your Own
- IBED requires patience and persistence, continuity and consistency
- Working with early-stage companies takes time
- A balanced portfolio economic development strategy is best!



Innovation Ecosystem



The concept of the **Innovation Ecosystem** stresses that the flow of technology and information among people, enterprises and institutions is key to a vibrant innovation process.

8



Small Business Facts

- SME's employ over 50% of the country's private sector workforce, hire 40% of high tech workers, such as scientists, engineers, and computer workers.
- The number of women-owned firms continues to grow at twice the rate of all U.S. firms (23% vs. 9%)
- 70% of SME's say retaining customers cheaper than getting new customers.
- 7 out of 10 new employer firms last about two years and about half survive five years.





Small Business Obstacles

- Lack of willingness or ability to take risks
- Time and effort required
- Raising capital
- Business management skills
- Knowledge about how to start a business
- Industry and market knowledge
- Pressure to keep a stable job

www.entrepreneur.com/dbimages/blog/entrepreneurship-risk.jpg



Small Business Keys to Success

Courage

The willingness to take risks

Perseverence

The capacity to power through tough times

Ambition

The insatiable drive to reach your goal

Understanding

The knowledge to make wise business decisions

Innovation

The ability to improve on existing ideas


www.entrepreneur.com/dbimages/blog/entrepreneurship-risk.jpg




Change is Inevitable

"It is not the strongest of species that survive, nor the most intelligent, but the ones most responsive to change."

Charles Darwin









What is A Road Map.....Why is it needed?

- A roadmap answers the question "Where do we want to be and how to we get there?"
- A cluster roadmap provides strategies and action plans to best achieve a
 vision of the future shared by a critical mass of industry-related
 organizations.
- The strategies and action plans are developed according to the unique strengths of the cluster and region as compared to a global market opportunity.





How BHI stimulates SME development in Maryland



An introduction to BioHealth Innovation an Innovation intermediary



State of Maryland: Federal & University Resources



- 59 Federal Laboratories, Centers,
 & Institutes in Maryland
- Maryland Federal R&D investment exceeding \$12 billion annually

JHU and USM represent another \$3.5 billion in annual R&D







The Region — Central Maryland

- Unrivaled Research Assets -
- Unfulfilled Commercial Promise -
























What is A Regional Innovation Intermediary?

An organization at the Center of the region's, state's and country's efforts to:

- Align local technologies, assets and resources
- Advance Innovation



- Regionally-oriented
- Private-public partnership, 501(c)(3) nonprofit
- Market-driven, private sector-led
- Neither a government initiative, nor a membership organization



Challenges to Innovation Economy

Lack of connection of innovation resources

Lack of an entrepreneurial culture and C-level executives

Lack of early-stage funding for commercializing technologies

Lack of spin-offs from federal and university R&D

BHI Value Proposition

Connects regional innovation assets

Develops an entrepreneurial talent and support pipeline

Attracts funding for technology commercialization

Evaluate commercially relevant federal and university technology



BHI Technology Focus

- Therapeutics
- Diagnostics
- Medical Devices
- Healthcare Services
- E-Health
- Mobile Health
- Electronic Medical Records
- Health Informatics
- BioHealth Cyber Security







BioHealth Regional Innovation Cluster Assets















































National Biodefense Analysis and Countermeasures Center
















BHI: An Innovation Intermediary that Connects





Regional BioHealth Ecosystem Partners

ACADEMIA

- RESEARCH/T2
- LIFELONG LEARNING
- ECONOMIC DEVELOPMENT

INDUSTRY

- PROFIT
- PROCESS
- PRODUCT

INSEPARABLE MISSIONS

GOVERNMENT

- SUSTAINABILITY
- INFRASTRUCTURE SUPPORT
 - ECONOMIC POLICY

FOUNDATIONS

- Economic Growth
- COMMUNITY INVESTMENT
- REGIONAL COLLABORATION



BHI Partners and Sponsors





























































BHI Board of Directors



Daniel J. Abdun-Nabi CEO, Emergent BioSolutions



Michael J. Baader, Esq. Managing Director Venable LLP



Richard A. Bendis President & CEO BioHealth Innovation, Inc.



Scott Carmer (Chair)
Exec. VP of Com. Operations
MedImmune



Kenneth Carter Chair Noble Life Sciences



Cynthia L. CollinsCEO
Clarient, GE Healthcare



Scott Dagenais Senior Vice President M&T Bank



Ronald J. Daniels President Johns Hopkins University



Jens Eckstein President SR One (GSK)



David M. Gillece (Secretary) Regional Managing Principal Cassidy Turley



Rick Ivey Vice PresidentR&D BD Diagnostics



William E. Kirwan Chancellor University System of MD



Douglas Liu Senior VP of GO Qiagen



David Mott General Partner New Enterprise Associates



William G. Robertson President & CEO Adventist Healthcare




J. Thomas Sadowski President & CEO EAGB



Thomas Street ACAO MoCo Government



BHI Organizational Chart





BHI Commercial Relevance Advisory Board




- 31 experienced biohealth professionals assisting BHI in evaluating market-relevant research and product development opportunities
- The CRAB will help determine the commercial applicability of emerging entrepreneurs, companies and their science or technology.



Innovation Paradigm Shift

PROOF OF CONCEPT
(Technological Feasibility)
Laboratory Push
"It Works!"

PROOF OF COMMERICAL RELEVANCE
(Market Pull)
"It Works To Solve A Problem"
"I'll Buy It"










Innovation Capital Valley of Death





Academic

State of Maryland

BHI Innovation Capital Map

Capital Sources by Investment Stage 4/12/2013 **Pre-Proof of** Translational Research / **Proof of Commercial** Seed / **Proof of Concept** Relevance / Pre-Seed Start-Up Concept **Early Stage Later Stage** \$3K - \$500K \$50K - \$1.5M \$25K - \$1.5M (over 5 years) \$15K - \$750K (over 3 years) \$200K - \$2M \$2M+ Maryland Venture Fund NCATS Cures Acceleration Maryland Industrial Partnerships Invest Maryland: Maryland Dingman Center Angels (UMD) NIH R01 (MIPS @ UMD) Network (CAN) Venture Fund Authority NIH R03 Propel Baltimore Fund BioMaryland Center Biotech -**TEDCO Technology** ABS Capital Partners SBIR/STTR Grant Phase I nology Development Awards Commercialization Fund NIH R21 BioMaryland Center Biotechnology - Commercialization **Greenspring Associates** Maryland Stem Cell Research **Development Awards** Maryland Innovation Initiative (MII) MII Phase 2 Grant Fund (MSCRF) - Translational Research Maryland Health Care Product (Managed by TEDCO) Novak Biddle **Development Corporation** MII Phase 3 Grant Venture Partners **TEDCO Technology Validation** SBIR / STTR Phase II Abell Venture Fund BHI SBIR/STTR Commercial **BHI Central Maryland** Sterling Venture Partners Relevance Program (CRP) **Angel Fund** JHU-Coulter Translational Research MMG Ventures LP Harbert Venture Partners Partnership ▲ BHI Commercial TDF Relevance Fund (CRF) JMI Equity New Enterprise Associates (NEA) **Associations** National Venture Capital Angel Capital Association Mid-Atlantic Venture Association of University Resource Parks (AURP) Association (MAVA) Association (NVCA) (ACA) Association of University Technology Managers (AUTM) Licensing Executive Society (LES) Tax Credits **Funding Type Key** Maryland Biotechnology

Private Capital

★ BioHealth Innovation, Inc.

Economic Development

Associations

Federal

Investor Tax Credit

Montgomery County Biotechnology Investor Tax Credit



BHI Commercialization Pipeline


Sources and evaluates biohealth intellectual properties (IP)

Funds marketrelevant IP **Grows** and markets businesses and products





BHI Commercialization Model





Partnership Intermediary Agreements



PIA between BHI and NIH's Office of Technology Transfer (OTT) that supports the 27 NIH institutes'\$\\$3\$ billion intramural research and the Food and Drug Administration to promote and foster cooperative research and accelerate technology commercialization among NIH/FDA, businesses, and universities.



PIA between BHI and the Telemedicine & Advanced Technology Research Center (TATRC) to capture USAMRMC and TATRC research outcomes and promote further research, product development, commercialization, and economic development opportunities. TATRC has funded 241 MD based projects over the last 12 years.



BHI Entrepreneur-in-Residence Program

A team leader who combines scientific, financial/VC and entrepreneurial management experience to:

- Perform due diligence
- Develop biohealth project-focused companies

Proactively identifies and commercializes **market-relevant** intellectual properties from:

- Federal Labs
- Universities
- Private Sector



Todd Chappell

Progress (1+ Years into Program)

- 97 Innovations identified and initially screened
- 72 NIH and 31 industry technology reviews conducted in 2013
- Entered into consulting agreement with Perceptive Navigation
- Entered into agreement with Ahead Research, Living Discoveries, Mimetas, N5 Sensors, and Perceptive Navigation
- Option Agreement for stem cell technology (JHU)
- Goal to fund the operation of more EIRs



EIR Criteria

- Senior management in an early stage life sciences startup
 - Entrepreneurial life science start up or spin out activity
- Management in a organization that specializes in startup companies
- Experience in a seed stage venture capital firm
- Served in a business development role in a high performing university or business development organization that successfully formed new ventures
- Served in a business development role, product development role, or other capacities for biotech products or services that enable substantial knowledge of the earliest stages of development for a new technology startup company



BHI Entrepreneurs-in-Residence



Todd Chappell (NIH-OTT)

Todd assists the Office of Technology Transfer (OTT) in the evaluation of existing technologies, provide an entrepreneurial perspective on new licensing proposals from start-up companies, advise on opportunities for new ventures, assist with developmental strategies, and mentor scientists to help ensure their research becomes commercially valuable.



Ken Malone (UM Ventures)

Ken has built his career on creating economic value from science. Whether it was developing new business lines for global corporations or spinning out new ventures from universities, he has engaged in the commercialization of hundreds of new products in advanced materials and life sciences.



Ram Aiyar (NHLBI)

Ram assists the National Heart Lung and Blood Institute (NHLBI) in translating disruptive science into commercially viable technologies. He works with the relevant stakeholders within the NIH to develop commercial plans and/or develop licensing opportunities such that the NIH technologies can be translated into commercially viable entities that will solve unmet medical needs of patients.




Rich Moore (BD Diagnostics)

Dr. Moore previously served as the Chief Scientific Officer for OpGen, Inc. In that role, Dr. Moore provided leadership over multiple R&D functions, and led the company's Scientific and Clinical Advisory Boards. Prior to that, he spent 12 years at BD Diagnostics holding various positions, most recently as R&D Director, Systems Integration and Advanced Technology.



The Startup Company Spectrum

Startup Spectrum





Different technologies = Different Strategies





EIR Expectations



- Assist OTT in the evaluation of existing technologies
- Provide an entrepreneurial perspective to OTT in its evaluation of new licensing proposals
- Advise OTT on opportunities for new ventures based on NIH/FDA technologies
- Assist with developmental strategies
- Mentor scientists to help ensure their research becomes commercially valuable



- Identify market viable innovations from NIH and other regional institutions
- Act as liaison among regional biohealth stakeholders and NIH
- Primary and secondary commercial analysis of lead technologies
- Develop novel technologies that are at conceptual stage
- Act as catalyst to license most interesting technologies and fund start-up companies



Maryland Universities/EIR Interaction



- \$5.8M budget
- 5 University partners
- 5 University site miners
- 40 University pre proof-ofconcept technologies funded
- \$25-\$150K funded per technology



- Regular meetings between BHI/EIR and site miners
- BHI identifies most commercially relevant technologies
- BHI and INNOVATE MD partnership opportunities
- BHI Commercial Relevance Advisory Board (CRAB)



EIR Expansion 2013





National Institutes of Health



University of Maryland Ventures EIR



National Heart Lung and Blood Institute



Industry EIR



Health Information Technology EIR



National Cancer Institute




National Institute of Allergy and Infections <u>Diseases</u>



National Institute on Drug Abuse



Early Stage Analysis of Commercial Relevance





Key Considerations for Technology Focus

- Clear unmet need that benefits public health
- First-in-class, best-in-class therapies
- Target therapeutic areas that reflect strategic objectives
- Clinical development advantage
- Relevance to strategic needs



Small Business Innovation Research (SBIR) Grant

- \$2.5 billion annual United States Government Program coordinated by the Small Business
- Administration Provides grants or contracts to small businesses to spur technological innovation
- Grants awarded in 3 Phases between \$150.000 and \$1 million
- Non-dilutive





BHI Innovation Capital

 SBIR/STTR Assistance Program - The BHI SBIR/STTR Assistance Program (in development) will provide assistance to biohealth-driven companies in the Central Maryland region in preparing for high-quality SBIR/STTR grant proposals for submission to federal funding agencies.


Metrics:

- Review 60 federal funding proposals per year
- Conduct 20 intensive assistance projects in 2013
- Track success measures through scoring, dollars, and leverage assistance.
- BHI Angel Fund The BHI Angel Fund (in development) will be a member-managed private equity investment fund serving the Central Maryland region entrepreneurial needs.
- BHI Commercial Relevance Investment Fund The BHI Commercial Relevance Investment Fund (in development) will help grow, attract, retain and connect Central Maryland biohealth innovation-based companies that need financing to grow their enterprises.



Health IT · · · Booming

- Increased investments in the <u>mobile and healthcare sectors</u> helped boost the median size of angel and angel group syndicate rounds
- Mobile health technologies projected to be worth \$11.8 billion by 2018





BHI Health IT Accelerator

A Health IT Accelerator is an intensive 16 week program that admits top-recruited companies and entrepreneurs, provides a curriculum and network of experienced mentors in business, marketing and product development in the Health IT arena to "accelerate" top companies.

- No HIT accelerators currently in Maryland
- Partner with Dreamit Ventures/JHU
- Located in a Central Maryland Co-Working space
- Retain promising high growth HIT entrepreneurs in MD
- Scheduled to launch in January 2014



Dreamlt Health Baltimore Accelerator


















US Venture Capital Investment



*VC firms completing 4 or more deals per year



US Angel Investment



Small Business Trends 50



BHI Commercial Relevance Fund

- Will provide direct seed and early-stage equity investments ranging from \$50,000 to \$1,000,000
- Focused on BioHealth companies that fall into the 4 categories:
 Therapeutics, Medical Devices, Diagnostics, and Health IT
- Goal: Achieve a \$10,000,000 to \$20,000,000 initial fund
- Expectation: 30% of companies generating 10x the original investment
- 2014 Identify Investors



BHI International Partnership with CFLD



- A professional enterprise group in investment and operation of industrial areas
- Entered into a Memorandum of Understanding (MOU) with BioHealth Innovation
 - Chinese-American EIR
 - Health Information Medical Technology Accelerator
 - Early Stage BioHealth Venture Capital Investment Fund



BHI President & CEO Rich Bendis after signing the MOU with CFLD President Ho



BHI International Soft Landing

- For international companies that want access to US agencies such as the NIH, FDA, MCNS, and others.
- Establish international EIRs to accelerate innovation
- Receive all the help necessary to establish a US subsidiary






Mimetas

- Created a new US subsidiary
- BHI is an equity partner
- Primary objective is to conduct business activities and research



BHI International Soft Landing



Riyadh?


North America

- Netherlands
- Germany
- China
- Korea
- Portugal
- South America

BHI offers international companies the perfect starting point to create US based subsidiaries by connecting them with BHI's extensive network.



BHI H-RIC Model



Health Regional Innovation Cluster (H-RIC)

- Regional, cluster-based economic development model
- Modeled after the Department of Energy's Regional Innovation Cluster
- Connects innovation assets to related industries
- Advances human health and economic prosperity
- Focuses on proof of commercial relevance



Entrepreneur's Resource and Finance Guide





Financing and Entrepreneurial Resource for Montgomery County and the Greater Baltimore Region

- Entrepreneur and Innovation Resource Network
- Innovator Financing Guide
- The Startup's Guide to **Intellectual Property**
- Federal Labs Listing





BHI Website and News



BHI Web site

The BHI Web site has news, an events calendar, research publications, regional organization feature stories and resources for the biohealth industry.

http://www.biohealthinnovation.org



BHI News

BHI's weekly e-newsletter highlights the Central Maryland Region's news articles, national biohealth trends and feature stories.

http://www.biohealthinnovation.org/news



BHI: The Triple Bottom Line

Grows high-paying jobs and businesses

Expands tax base; improves economic vitality

... and Benefits human health!



BHI Key Staff

BioHealth Innovation, Inc.

22 Baltimore Road | Rockville, MD 20850

bhi@biohealthinnovation.org



The Wire Hardware store
- BHI's Office Space

Richard Bendis

President & CEO (215) 593-3333 rbendis@biohealthinnovation.org

Todd Chappell

EIR, NIH-OTT (978) 933-1622 tchappell@biohealthinnovation.org

Ken Malone

EIR, UM Ventures (601) 466-7050 kmalone@biohealthinnovation.org

Ram Aiyar

EIR, NHLBI (301) 624-5505 raiyar@biohealthinnovation.org

Richard Moore

EIR, BD Diagnostics (301) 637-3385 rmoore@biohealthinnovation.org

Ethan Byler

Director, Innovation Programs (301) 637-7952 ebyler@biohealthinnovation.org

Amanda Wilson

Operations Manager (301) 637-0699 awilson@biohealthinnovation.org

Ren é e Enright

Executive Administrator (301) 637-5372 renright@biohealthinnovation.org

Eric Norman

EIR Program Consultant (301) 594-7219 Eric.Norman@nih.gov

Adam Hafez

IT Manager (301) 637-7270 ahafez@biohealthinnovation.org

Arielle Dolegui

Business Research Analyst (301) 637-3381 adolegui@biohealthinnovation.org